AT1 antagonists: A patent review (2008 - 2012)

Expert Opinion on Therapeutic Patents

Volumn 23, Issue 11, 2013, Pages 1483-1494

  Mavromoustakos, Thomas ^a   Agelis, George ^b,d   Durdagi, Serdar ^c  

^a UNIVERSITY OF ATHENS   (Greece)

^b UNIVERSITY OF PATRAS   (Greece)

^c BAHCESEHIR UNIVERSITY   (Turkey)

^d Eldrug SA   (Greece)

Author keywords

Angiotensin II; AT1 receptor; RAS system; Sartans

Indexed keywords

ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN II; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; AZILSARTAN; CANDESARTAN; CANDESARTAN HEXETIL; COLLAGEN TYPE 1; CYCLODEXTRIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPROSARTAN; GESTAGEN; IMIDAZOLE; IRBESARTAN; ISOSORBIDE DINITRATE; LIPOSOME; LOSARTAN; NITRIC OXIDE DONOR; OLMESARTAN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; POLYMER; RAMIPRIL; RAMIPRILAT; REACTIVE OXYGEN METABOLITE; SARTAN DERIVATIVE; TELMISARTAN; UNINDEXED DRUG; VALSARTAN;

ALKYLATION; ALZHEIMER DISEASE; ANGINA PECTORIS; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; BIOLOGICAL ACTIVITY; CARDIOVASCULAR DISEASE; COGNITION; COGNITIVE DEFECT; CONGESTIVE HEART FAILURE; CREATININE BLOOD LEVEL; DIABETIC NEUROPATHY; DISEASE SEVERITY; DRUG DESIGN; DRUG MECHANISM; DYSLIPIDEMIA; GENE EXPRESSION; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HEART FAILURE; HEART FUNCTION; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPERURICEMIA; INFLAMMATION; INSULIN RELEASE; KIDNEY FAILURE; KIDNEY FIBROSIS; KIDNEY ISCHEMIA; LIPID BILAYER; LIPIDOMICS; MOLECULAR MODEL; MOTONEURON; NONHUMAN; PHARMACOPHORE; PHYSICAL CHEMISTRY; PULMONARY HYPERTENSION; REVIEW; SKIN DISEASE; SYSTOLIC BLOOD PRESSURE; THROMBOCYTE AGGREGATION; THROMBOSIS;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; CHEMISTRY, PHARMACEUTICAL; DRUG COMBINATIONS; DRUG DISCOVERY; HUMANS; HYPERTENSION; MODELS, MOLECULAR; OXAZOLES; PATENTS AS TOPIC; RENIN-ANGIOTENSIN SYSTEM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84886932485     PISSN: 13543776     EISSN: 17447674     Source Type: Journal    
DOI: 10.1517/13543776.2013.830104     Document Type: Review

References (74)

1. Dasgupta C, Zhang L. Angiotensin II receptors and drug discovery in cardiovascular disease. Drug Discov Today 2011;16:22-34
2. Lang CC, Struthers DA. Targeting the renin Angiotensin Aldosterone system in heart failure. Nat Rev Cardiol 2013;10:125-34
3. Pessôa BS, Van der Lubbe N, Verdonk K, et al. Key developments in renin-Angiotensin aldosterone system. Nat Rev Nephrol 2013;9:26-36
4. Naik P, Murumkar P, Giridhar R, et al. Angiotensin II receptor type 1 (AT1) selective nonpeptidic antagonists - a perspective. Bioorg Med Chem 2010;18:8418-56
5. Tsukamoto O, Kitakaze M. It is time to reconsider the cardiovascular protection afforded by RAAS blockade-overview of RAAS systems. Cardiovasc Drugs Ther 2013;27:133-8
6. Akazawa H, Yabumoto C, Yano M, et al. ARB and cardioprotection. Cardiovasc Drugs Ther 2013;27:155-60
7. Steckelings UM, Paulis L, Unger T, et al. Emerging drugs which target rennin-Angiotensin-Aldosterone system. Expert Opin Emerg Drugs 2011;16:619-30
8. Castan C, Guimberteau F, Meyrueix R, et al. Multimicroparticulate oral pharmaceutical form with modified release of angiotensin II receptor antagonists. US0311315; 2009
9. Kordikowski A, Saez Munoz C, Ventosa Rull C, et al. Method for preparing amorphous combinations of Angiotensin II receptor antagonists and diuretics. WO125028; 2009
10. Ruben Dario Sinisterra M, Robston Augusto Souza DS, Frederic Jean Georges F, et al. Preparation of formulations of Angiotensin II AT1 receptors antagonists for the treatment of arterial hypertension, other cardiovascular illnesses and its complications. US0091541; 2011
11. Castan C, Guimberteau F, Meyrueix R, et al. Multimicroparticulate oral pharmaceutical form with modified release of angiotensin II receptor antagonists. US0311315; 2009
12. Ruben D, Sinistera M, Robson Augusto DS, et al. Preparation of formulations of angiotensin II AT1 receptors antagonists for the treatment of arterial hypertension, other cardiovascular illnesses and its complications. US08293723; 2012
13. Allison M, Gatlin MR. Pharmaceutical compositions of an AT1-receptor antagonist and insulin secretion enhancer. US07687528; 2010
14. Madan S, Rathinasabarthy V, Arora VK. Orally disintegrating compositions comprising antihypertensive agents. WO146551; 2010
15. Claudel S, Gaudin C. Method for managing the risks associated with an increase in serum creatinine during dronedarone treatment. EP2116239; 2009
16. Bergmann A. Method for the identification of patients in need of therapy having minor cognitive disorders and the treatment of such patients. US0039343; 2011
17. Melani F, Giuliani S, Maggi Carlo A. Association of xanthine oxidase inhibitors and Angiotensin II receptor antagonists and use thereof. WO141431; 2011
18. Pershadsingh HA. Novel PRAP ligands that do not cause fluid retention, edema or congestive heart failure. US0094913; 2012
19. Bonnichsen R. Cosmetic and pharmaceutical compositions comprising ACE inhibitors and/or angiotensin II receptor antagonists. US0219514; 2012
20. Jensen BV, Bonnichsen R. Use of ACE inhibitors and/or angiotensin II receptor antagonists for the improving and/or maintaining the skin tone and for the treatment of skin ageing. US0143458; 2009
21. Staudinger HW, Khanskaya IV, Sadeh J. Methods of treating COPD. MX006089; 2010
22. Baum T, Daniel H, Showalter H. Compositions and methods for treating inflammation conditions of the bowel. WO017312; 2010
23. Cheng ZJ, Vapaatalo H, Mervaala E. Angiotensin II and vascular inflammation. Med Sci Monit 2005;11:194-205
24. Dandona P, Dhindsa S, Ghanim H, et al. Angiotensin II and inflammation: The effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockade. J Hum Hyp 2007;21:20-7
25. Worcel M, Sagbolinski ML. Compositions and methods related to heart failure. US0118294; 2009
26. Schlinger R, Avramoff A. Process for forming solid oral dosage forms of angiotensin II receptor antagonists. US0278909; 2010
27. Anderson G, Yusuf S, Hilbrich L. Pharmaceutical combination of angiotensin II antagonists and angiotensin I converting enzyme inhibitors. US 0114046; 2008
28. Iyer EK, Rasendra JHA-KJ, Jain GK, et al. Cardiovascular combinations using renin-Angiotensin inhibitors. WO010008; 2008
29. Garvey DS, Xiong C, Chia-En L, et al. Organic nitric oxide enhancing salts of angiotensin II antagonists compositions and methods of use. US0215838; 2009
30. Garvey DS. Cardiovascular compounds comprising nitric oxide enhancing groups, compositions and methods of use. US0012057; 2009
31. Notelovitz M, Bennink HJTC, Boerrigter PJ. Treatment of prevention of unscheduled bleeding in women on progestogen containing medication. US0197843; 2009
32. Norbert B, Hertzel G, Salim Y. Use of angiotensin II type 1 receptor antagonists for the prevention of stroke, diabetes and/or congestive heart failure. EP2277519; 2011
33. Wu HH, City X. Lead compound of anti-hypertensive drug and method for screening the same. US0221617; 2009
34. Mahima P, Sarvesh P. In silico identification of novel lead compounds with AT1 receptor antagonist activity: Successful application of chemical database screening protocol. Org Med Chem Lett. 2012.2(1):7
35. Matsoukas J, Gavras C, Vlachakos D, et al. Compounds. WO016515; 2009
36. Matsoukas J, Maragoudakis M, Vlachakos D, et al. 1,3,5-substituted imidazoles and their use in the treatment of hypertension and methods for their preparation. MX012755; 2009
37. Matsoukas J, Gavras C, Vlachakos D, et al. 1,3 and 1,3,5 substituted imidazoles as antihypertensives. US0216854; 2010
38. Matsoukas J, Maragoudakis M, Vlachakos D. Angiotensin II receptor antagonists based on 4(5) substituted imidazoles and transdermal delivery in the treatment of hypertension and cardiovascular diseases. GR0100312B; 2007
39. Roumelioti P, Resvani A, Durdagi S, et al. An efficient synthesis of a rationally design 1,5 disubstituted imidazole AT1 angiotensin receptor antagonist: Reorientation of imidazole pharmacophore groups in losartan reserves high receptor affinity and confirms docking studies. J Comput Aided Mol Des 2010;24:749-58
40. Agelis G, Resvani A, Matsoukas A, et al. Towards non-peptide Ang II AT1 receptor antagonists based on urocanic acid: Rational design, synthesis and biological evaluation. Aminoacids 2011;40:411-20
41. Agelis G, Resvani A, Durdagi S, et al. The discovery of new potent non-peptide Angiotensin II AT1 receptor blockers: A concise synthesis, molecular docking studies and biological evaluation of N-substituted 5-butylimidazole derivatives. Eur J Med Chem 2012;55:358-74
42. Agelis G, Resvani A, Koukoulitsa C, et al. Rational design, efficient syntheses and biological evaluation of N, N'-symmetrically bis-substituted butylimidazole analogs as a new class of potent angiotensin II receptor blockers. Eur J Med Chem 2013;62:352-70
43. Mavromoustakos T, Agelis G, Resvani A, et al. Interactions of the potent synthetic AT1 antagonist analog BV6 with membrane bilayers and mesoporous silicate matrices. Biochim Biophys Acta 2013;1828:1846-55
44. Brooks C, Cheung M, Goodman K, et al. TRPV4 antagonists. WO174340; 2012
45. Amjad A, Freehold NJ, Lo MM-C, et al. Angiotensin II receptor antagonists. US0238608; 2012
46. Amjad A, Freehold NJ, Lo MM-C, et al. Angiotensin II receptor antagonists. WO140111; 2009
47. Amjad A, Lo MM-C, Franklin CQ, et al. Angiotensin II receptor antagonists. US0201621; 2011
48. Amjad A, Franklin CQ, Lo MM-C, Whitehead BR. Angiotensin II receptor antagonists. WO094242; 2009
49. Amjad A, Lo MM-C, Franklin CQ, et al. Angiotensin II receptor antagonists. WO070241; 2009
50. Almirante N, Ferrario M, Stefanini S, et al. Angiotensin II receptor antagonists. WO150007; 2009
51. Schiesser CH, Hsin IP, Ziogas J, et al. Novel Biphenyl Sartans. WO134019; 2011
52. Tan NP, Taylor MK, Bottle SE, et al. Novel paramagnetic AT1 receptor antagonists. Chem Commun 2011;47:12083-5
53. Min LJ, Mogi M, Shudou M, et al. Peroxisome proliferator-Activated receptor-g activation with angiotensin II type 1 receptor blockade is pivotal for the prevention of blood-brain barrier impairment and cognitive decline in type 2 diabetic mice. Hypertension 2012;59:1079-88
54. Martin MC, Foster MC, Brunner HR, et al. A systematic comparison of the properties of clinically used angiotensin II type 1 receptor antagonists. Pharmacol Rev 2013;65:809-48
55. Benson CS, Pershadsingh HA, Ho CI, et al. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARg-modulating activity. Hypertension 2004;43:993-1002
56. Schupp M, Janke J, Clasen R. Angiotensin type 1 receptor blockers induce peroxisome proliferator activated receptor-g activity. Circulation 2004;109:2054-7
57. Miura T, Higashimurayama S, Tagashira J, et al. Novel 2-pyridone derivative and pharmaceutical product containing same. US0225896; 2012
58. Miura T, Higashimurayama S, Kazuhiro O, et al. Compound containing a novel 4-Alkoxypyrimidine structure and medicine containing same. US0322819; 2012
59. Miura T, Higashimurayama S, Kazuhiro O, et al. Novel sulfonamide derivative and pharmaceutical product containing same. US0122906; 2012
60. Fatheree PR, Hudson R, Murray R, et al. Dual-Acting oxazole antihypertensive agents. US8372984; 2013
61. Kim JH, Lee JH, Paik SH, et al. Fimasartan, a novel angiotensin II receptor antagonist. Arch Pharm Res 2012;35:1123-6
62. Burnier M. Angiotensin II type 1 receptor blockers. Circulation 2001;103:904-12
63. Cappelo B, Di Maio C, Iervolino M, Miro A. Improvement of solubility and stability of valsartan by hydroxypropyl-b-cyclodextrin. J Incl Phenom Macro 2006;54:289-94
64. Tzoupis H, Leonis G, Megariotis G, et al. Dual inhibitors for aspartic proteases HIV-1 PR and renin: Advancements in AIDS-hypertension-diabetes linkage via molecular dynamics, inhibition assays, and binding free energy calculations. J Med Chem 2012;55:5784-96
65. Fotakis C, Megariotis G, Christodouleas D, et al. Comparative study of the AT1 receptor prodrug antagonist candesartan cilexetil with other sartans on the interactions with membrane bilayers. Biochim Biophys Acta 2012;1818:3107-20
66. Ntountaniotis D, Mali G, Grdadolnik SG, et al. Thermal, dynamic and structural properties of drug AT1 antagonist olmesartan in lipid bilayers. Biochim Biophys Acta 2011;808:2995-3006
67. Fotakis C, Christodouleas D, Zoumpoulakis P, et al. Comparative biophysical studies of sartan class drug molecules losartan and candesartan (CV- 11974) with membrane bilayers. J Phys Chem B 2011;115:6180-92
68. Mavromoustakos T, Chatzigeorgiou P, Koukoulitsa C, et al. Partial interdigitation of lipid bilayers. Int J Quantum Chem 2011;6:1172-83
69. Potamitis C, Chatzigeorgiou P, Siapi E, et al. Interactions of the AT1 antagonist valsartan with dipalmitoyl-phosphatidylcholine bilayers. Biochim Biophys Acta 2011;1808:1753-63
70. Potamitis C, Zervou M, Katsiaras V, et al. Antihypertensive drug valsartan in solution and at the AT1 receptor: Conformational analysis, dynamic NMR spectroscopy, in silico docking and molecular dynamics simulations. J Chem Inf Model 2009;49:726-39
71. Agelis D, Resvani A, Durdagi S, et al. The discovery of new potent non-peptide Angiotensin II AT1 receptor blockers: A concise synthesis, molecular docking studies and biological evaluation of N-substituted 5-butylimidazole derivatives. Eur J Med Chem 2012;55:358-74
72. Politi A, Durdagi S, Moutevelis- Minakaki P, et al. Development of accurate binding affinity predictions of novel renin inhibitors through molecular docking studies. J Mole Graph & Model 2010;29:425-35
73. Politi A, Durdagi S, Moutevelis- Minakaki P, et al. Application of 3D QSAR CoMFA/CoMSIA and in silico docking studies on novel renin inhibitors against cardiovascular diseases. Euro J Med Chem 2009;44:3703-11
74. Agelis G, Roumelioti P, Resvani A, et al. An efficient synthesis of a rationally designed 1,5 disubstituted imidazole AT (1) Angiotensin II receptor antagonist: Reorientation of imidazole pharmacophore groups in losartan reserves high receptor affinity and confirms docking studies. J Comput Aided Mole Des 2010;49:726-39